Vfend (voriconazole tablets and oral suspension) — Cigna
Fungal Infection (Systemic) in a Patient with Graft-versus-Host Disease – Prophylaxis
Preferred products
- generic voriconazole tablets
- generic voriconazole oral suspension
Initial criteria
- Request is for Vfend (voriconazole tablets or oral suspension) or generic voriconazole tablets or oral suspension
- Patient meets the indication criteria listed (either FDA-approved or supported use)
- When clinically appropriate, the patient is directed to try the generic voriconazole (Step 1) prior to brand Vfend (Step 2)
Reauthorization criteria
- Continuation of therapy to complete the approved course
Approval duration
3–12 months (as specified per indication)